Jun Xu

Title: Jun Xu - Innovator in Protein-Protein Interaction Inhibitors

Introduction

Jun Xu is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors that target protein-protein interactions. His work is crucial for advancing therapeutic options for diseases such as leukemia.

Latest Patents

Jun Xu holds a patent for an "Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof." This patent discloses a WDR5 protein-protein interaction inhibitor, which includes a compound represented by a specific structural formula. Experimental results indicate that this inhibitor selectively acts on WDR5 and its interacting proteins, such as MLL, to inhibit the proliferation of leukemia cells. Additionally, it affects the methylation of H3K4 and the expression of downstream Hox/Meis-1 genes at the cellular level. The patent also outlines a method for preparing the inhibitor and its potential use in developing drugs for treating acute leukemia and related diseases.

Career Highlights

Jun Xu is affiliated with China Pharmaceutical University, where he continues to engage in innovative research. His work has garnered attention for its potential impact on cancer treatment, particularly in targeting specific protein interactions that play a role in disease progression.

Collaborations

Jun Xu collaborates with notable colleagues, including Qidong You and Xiaoke Guo. Their combined expertise enhances the research efforts at China Pharmaceutical University and contributes to the advancement of therapeutic strategies.

Conclusion

Jun Xu's innovative work in developing protein-protein interaction inhibitors represents a significant advancement in the field of biochemistry. His contributions have the potential to lead to new treatments for acute leukemia and other related diseases.